Adaptive Biotechnologies Corp vs Carnival Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25 (market cap $4.04B), while Carnival Corp trades at $27.83 (market cap $37.98B). The key difference: Carnival Corp is far larger — about 9.4× Adaptive Biotechnologies Corp's market cap, and Carnival Corp pays a 1.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CCL | |
|---|---|---|
Market Cap | $4.04B | $37.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $33.99 |
52-Week Low | $12.30 | $23.89 |
Enterprise Value | $4.10B | $61.91B |
Dividend Yield | — | 1.62% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Carnival Corporation (CCL) trades at $27.75, down 4.28% today, amid a bearish technical signal. The company shows strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, net income turning positive to $2.76B, and positive cash flow of $727M in 2025. Recent earnings beats and a 59.57% analyst buy rating support optimism, though technical indicators show near-term pressure with support at $27.
Outlook remains positive driven by record travel demand, fleet expansion, and debt reduction, with a consensus price target of $35.18 offering 27% upside. Key risks include fuel price volatility, economic sensitivity, and execution of growth plans amid competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →